Short Interest in Icosavax, Inc. (NASDAQ:ICVX) Increases By 27.9%

Icosavax, Inc. (NASDAQ:ICVXGet Rating) saw a large increase in short interest in March. As of March 31st, there was short interest totalling 1,090,000 shares, an increase of 27.9% from the March 15th total of 852,200 shares. Based on an average daily volume of 379,700 shares, the days-to-cover ratio is currently 2.9 days.

Icosavax stock traded down $0.26 during trading hours on Monday, hitting $9.63. The stock had a trading volume of 11,959 shares, compared to its average volume of 358,033. Icosavax has a one year low of $4.00 and a one year high of $49.99. The business’s 50 day simple moving average is $13.52 and its 200-day simple moving average is $19.82.

Icosavax (NASDAQ:ICVXGet Rating) last issued its quarterly earnings data on Wednesday, March 30th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.04). The firm had revenue of $2.07 million during the quarter, compared to the consensus estimate of $1.80 million. As a group, analysts predict that Icosavax will post -2.08 earnings per share for the current fiscal year.

Separately, Zacks Investment Research lowered Icosavax from a “buy” rating to a “hold” rating in a research note on Tuesday, March 1st. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $48.57.

In related news, Director Mark Mcdade bought 42,225 shares of Icosavax stock in a transaction dated Friday, April 1st. The shares were bought at an average cost of $7.10 per share, with a total value of $299,797.50. Following the acquisition, the director now owns 50,243 shares in the company, valued at approximately $356,725.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Cassia Cearley sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 7th. The shares were sold at an average price of $17.16, for a total value of $171,600.00. The disclosure for this sale can be found here.

Several large investors have recently made changes to their positions in the stock. Rock Springs Capital Management LP bought a new stake in shares of Icosavax in the third quarter valued at $21,725,000. Deutsche Bank AG bought a new stake in shares of Icosavax during the 3rd quarter valued at $241,000. New York State Common Retirement Fund bought a new stake in shares of Icosavax during the 3rd quarter valued at $180,000. Laurion Capital Management LP bought a new stake in shares of Icosavax during the 3rd quarter valued at $22,193,000. Finally, TD Asset Management Inc. bought a new stake in shares of Icosavax during the 3rd quarter valued at $445,000. 59.07% of the stock is currently owned by institutional investors.

About Icosavax (Get Rating)

Icosavax, Inc, a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial.

Further Reading

Receive News & Ratings for Icosavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icosavax and related companies with MarketBeat.com's FREE daily email newsletter.